Gili Regev-Yochay

Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Naïve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study.

Joseph G, Cohen C, Rubin C, Murad H, Indenbaum V, Asraf K, Weiss-Ottolenghi Y, Segal-Lieberman G, Kreiss Y, Lustig Y, Regev-Yochay G.

Microorganisms. 2023 Jun 22. 11(7). PMID: 37512801

Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel.

Gilboa M, Gonen T, Barda N, Cohn S, Indenbaum V, Weiss-Ottolenghi Y, Amit S, Asraf K, Joseph G, Levin T, Kanaaneh Y, Aydenzon A, Canetti M, Freedman L, Zuckerman N, Mendelson E, Doolman R, Kreiss Y, Regev-Yochay G, Lustig Y.

JAMA Netw Open. 2023 05 01. 6(5):e2314757. PMID: 37219906

The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Barda N, Canetti M, Gilboa M, Asraf K, Indenboim V, Weiss-Ottolenghi Y, Amit S, Zubli D, Doolman R, Mendelson E, Freedman LS, Kreiss Y, Lustig Y, Regev-Yochay G.

Clin Infect Dis. 2023 04 03. 76(7):1315-1317. PMID: 36366729

Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up.

Canetti M, Barda N, Gilboa M, Indenbaum V, Mandelboim M, Gonen T, Asraf K, Weiss-Ottolenghi Y, Amit S, Doolman R, Mendelson E, Harats D, Freedman LS, Kreiss Y, Lustig Y, Regev-Yochay G.

Nat Commun. 2023 Mar 22. 14(1):1593. PMID: 36949080

Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study.

Regev-Yochay G, Lustig Y, Joseph G, Gilboa M, Barda N, Gens I, Indenbaum V, Halpern O, Katz-Likvornik S, Levin T, Kanaaneh Y, Asraf K, Amit S, Rubin C, Ziv A, Koren R, Mandelboim M, Tokayer NH, Meltzer L, Doolman R, Mendelson E, Alroy-Preis S, Kreiss Y.

Lancet Microbe. 2023 05. 4(5):e309-e318. PMID: 36963419

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up.

Barda N, Lustig Y, Indenbaum V, Zibly D, Joseph G, Asraf K, Weiss-Ottolenghi Y, Amit S, Kliker L, Abd Elkader B, Ben-Ami E, Canetti M, Koren R, Katz-Likvornik S, Halpern O, Mendelson E, Doolman R, Harats D, Kreiss Y, Mandelboim M, Regev-Yochay G.

Clin Microbiol Infect. 2023 Jul. 29(7):918-923. PMID: 36921715

The Use of Rapid COVID-19 Antigen Test in the Emergency Department as a Decision-Support Tool.

Meltzer L, Amit S, Gilboa M, Tal I, Mechnik B, Irony A, Engelrad H, Epstein A, Frenkel-Nir Y, Levy Y, Kreiss Y, Regev-Yochay G.

Microorganisms. 2023 Jan 21. 11(2). PMID: 36838249

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients.

Davidov Y, Indenbaum V, Mandelboim M, Asraf K, Gonen T, Tsaraf K, Cohen-Ezra O, Likhter M, Nemet I, Kliker L, Mor O, Doolman R, Cohen C, Afek A, Kreiss Y, Regev-Yochay G, Lustig Y, Ben-Ari Z.

Viruses. 2023 Jan 16. 15(1). PMID: 36680292

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up.

Canetti M, Barda N, Gilboa M, Indenbaum V, Mandelboim M, Gonen T, Asraf K, Weiss-Ottolenghi Y, Amit S, Doolman R, Mendelson E, Harats D, Freedman LS, Kreiss Y, Lustig Y, Regev-Yochay G.

Nat Commun. 2022 12 13. 13(1):7711. PMID: 36513665

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients.

Davidov Y, Indenbaum V, Atari N, Kliker L, Tsaraf K, Asraf K, Cohen-Ezra O, Likhter M, Mor O, Doolman R, Weiss-Ottolenghi Y, Hod T, Afek A, Kreiss Y, Lustig Y, Regev-Yochay G, Mandelboim M, Ben-Ari Z.

Viruses. 2022 12 12. 14(12). PMID: 36560773